Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.
Hagey RJ, Elazar M, Pham EA, Tian S, Ben-Avi L, Bernardin-Souibgui C, Yee MF, Moreira FR, Rabinovitch MV, Meganck RM, Fram B, Beck A, Gibson SA, Lam G, Devera J, Kladwang W, Nguyen K, Xiong A, Schaffert S, Avisar T, Liu P, Rustagi A, Fichtenbaum CJ, Pang PS, Khatri P, Tseng CT, Taubenberger JK, Blish CA, Hurst BL, Sheahan TP, Das R, Glenn JS.
Hagey RJ, et al. Among authors: taubenberger jk.
Nat Med. 2022 Sep;28(9):1944-1955. doi: 10.1038/s41591-022-01908-x. Epub 2022 Aug 18.
Nat Med. 2022.
PMID: 35982307
Free PMC article.
These findings highlight the potential applicability of this approach to any virus of interest via a process we term 'programmable antivirals', with implications for antiviral prophylaxis and post-exposure therapy....
These findings highlight the potential applicability of this approach to any virus of interest via a process we term 'programmable an …